TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8561070

Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acid‐rich fish oil supplement for 21 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acid‐rich fish oil supplement with interferon‐gamma incubation
Number of subjects: 12

Group type: COMPARATOR
Intervention: No supplement (control group)
Number of subjects: 12
Study: 1907839

Group type: EXPERIMENTAL
Intervention: Pravastatin with propranolol (40 mg twice daily)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lovastatin with propranolol (40 mg twice daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lovastatin
Number of subjects: 16
Study: 6125188

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Atenolol and Propranolol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Atenolol, Propranolol, and Pindolol
Number of subjects: 19
Study: 29462231

Group type: EXPERIMENTAL
Intervention: apremilast 30 mg twice daily
Number of subjects: 136

Group type: COMPARATOR
Intervention: placebo (switched to apremilast after 16 weeks)
Number of subjects: 136
Study: 28077530

Group type: EXPERIMENTAL
Intervention: Maize-derived HES solution
Number of subjects: 118

Group type: COMPARATOR
Intervention: Potato-derived HES solution
Number of subjects: 118
Study: 24548148

Group type: EXPERIMENTAL
Intervention: Listening to preferred music during flexible cystoscopy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (unable to listen to music)
Number of subjects: 124
Study: 22903145

Group type: EXPERIMENTAL
Intervention: Action Planning (AP) program
Number of subjects: 2031

Group type: EXPERIMENTAL
Intervention: Action Planning plus (AP+) program
Number of subjects: 2031

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2031
Study: 20694935

Group type: EXPERIMENTAL
Intervention: Elite race car drivers
Number of subjects: 26

Group type: COMPARATOR
Intervention: Physically active controls
Number of subjects: 26
Study: 19008724

Group type: EXPERIMENTAL
Intervention: moxonidine (0.3 mg twice daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: atenolol (50 mg once daily)
Number of subjects: 87
Study: 15705324

Group type: EXPERIMENTAL
Intervention: Mycobacterium haemophilum-specific PCR
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Real-time PCR
Number of subjects: 89

Group type: COMPARATOR
Intervention: Culture
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: M. avium detection
Number of subjects: 89
Study: 14571069

Group type: EXPERIMENTAL
Intervention: Moisturizing cream applied twice daily for 6 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-treated control side
Number of subjects: 16
Study: 10799371

Group type: COMPARATOR
Intervention: Black tea
Number of subjects: 20

Group type: COMPARATOR
Intervention: Green tea
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Urinary 4-O-methylgallic acid
Number of subjects: 20
Study: 8637438

Group type: EXPERIMENTAL
Intervention: Low-glycemic-index diet (LGI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: High-glycemic-index diet (HGI)
Number of subjects: 32
Study: 1360558

Group type: EXPERIMENTAL
Intervention: Active negative pressure ventilation (NPV)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Sham negative pressure ventilation (NPV)
Number of subjects: 184
Study: 3909132

Group type: EXPERIMENTAL
Intervention: i.m. meptazinol (50, 100, 200mg)
Number of subjects: 128

Group type: COMPARATOR
Intervention: i.m. morphine (4, 8 and 16 mg)
Number of subjects: 128
Study: 30834812

Group type: EXPERIMENTAL
Intervention: Unilateral hybrid therapy (UHT; unilateral robot‐assisted therapy + modified constraint‐induced movement therapy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bilateral hybrid therapy (BHT; bilateral robot‐assisted therapy + bilateral arm training)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Robot therapy (RT)
Number of subjects: 30
Study: 29423521

Group type: EXPERIMENTAL
Intervention: Sym004, 12 mg/kg/wk (arm A)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Sym004, 9 mg/kg loading dose followed by 6 mg/kg/wk (arm B)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Investigator's choice of treatment (arm C)
Number of subjects: 254
Study: 26813548

Group type: EXPERIMENTAL
Intervention: β-blocker (BB) treatment (any molecule and any dose)
Number of subjects: 2622

Group type: COMPARATOR
Intervention: Non-BB treatment
Number of subjects: 2622
Study: 25100236

Group type: EXPERIMENTAL
Intervention: rosuvastatin (5 or 2.5 mg/day)
Number of subjects: 143

Group type: COMPARATOR
Intervention: non-statin group
Number of subjects: 143
Study: 22883585

Group type: EXPERIMENTAL
Intervention: Heparin gelatin sponge stickers
Number of subjects: 79

Group type: COMPARATOR
Intervention: Conservative traditional drying method
Number of subjects: 79
Study: 21059972

Group type: EXPERIMENTAL
Intervention: Twice-a-week supervised aerobic and resistance training plus structured exercise counseling
Number of subjects: 606

Group type: COMPARATOR
Intervention: Counseling alone (control group)
Number of subjects: 606
Study: 17561440

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 53

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 53
Study: 15769489

Group type: EXPERIMENTAL
Intervention: Individuals with Parkinson's disease (PD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 32
Study: 10855156

Group type: EXPERIMENTAL
Intervention: Longitudinal case management by professional nurses
Number of subjects: 0
Study: 9095400

Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 300 mg twice daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride
Number of subjects: 11
Study: 8466688

Group type: EXPERIMENTAL
Intervention: Relapse Prevention (RP)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Brief Intervention (BI)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 95
Study: 3514124

Group type: EXPERIMENTAL
Intervention: Open two‐bottle systems
Number of subjects: 43

Group type: COMPARATOR
Intervention: Closed systems
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Open system
Number of subjects: 43

Group type: COMPARATOR
Intervention: Closed system
Number of subjects: 43
Study: 29933562

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 500U
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 27680049

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy associated with Essential Fatty Acids
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study: 23803884

Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (0.32%, 0.64%, and 0.96% of total fatty acids, with ARA at 0.64%)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (no LCPUFA supplementation)
Number of subjects: 81
Study: 20189659

Group type: EXPERIMENTAL
Intervention: Endotracheal tube cuff lidocaine (2% lidocaine)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Intravenous lidocaine (1.5mg/kg of 2% lidocaine)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Endotracheal tube cuff saline
Number of subjects: 176

Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 176
Study: 18925883

Group type: EXPERIMENTAL
Intervention: Varicella immunization (0.7% immunized)
Number of subjects: 2184

Group type: EXPERIMENTAL
Intervention: Pertussis immunization (1.7% nonimmunized)
Number of subjects: 2184

Group type: EXPERIMENTAL
Intervention: Cumulative received vaccine doses
Number of subjects: 2184

Group type: COMPARATOR
Intervention: Common childhood immunization in the first year
Number of subjects: 2184
Study: 16687966

Group type: EXPERIMENTAL
Intervention: Combination therapy with amlodipine besylate/benazepril hydrochloride 5/20 mg
Number of subjects: 505

Group type: COMPARATOR
Intervention: Amlodipine besylate 5 mg
Number of subjects: 505

Group type: COMPARATOR
Intervention: Benazepril hydrochloride 20 mg
Number of subjects: 505
Study: 14660988

Group type: EXPERIMENTAL
Intervention: Evidence-based intervention to general practitioners incorporating multidisciplinary telephone case conferencing
Number of subjects: 1455

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1455
Study: 11075844

Group type: EXPERIMENTAL
Intervention: Almotriptan 6.25 mg
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Almotriptan (both doses)
Number of subjects: 1013
Study: 9364179

Group type: EXPERIMENTAL
Intervention: Protective gloves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protective covers for the lower arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hospitalisation rate for hand and lower arm injuries
Number of subjects: 0
Study: 1411094

Group type: EXPERIMENTAL
Intervention: Puppet shadow play (wayang) incorporating the arthritis community education (ACE)
Number of subjects: 1105

Group type: COMPARATOR
Intervention: Control group (matched for age, sex, and educational level who did not see the play)
Number of subjects: 1105
Study: 3490176

Group type: EXPERIMENTAL
Intervention: Calcitriol (4 micrograms/kg intravenously on entry and on the second and third study days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no calcitriol)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 24
Study: 28993261

Group type: EXPERIMENTAL
Intervention: Low-FODMAP diet (n = 46)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Sham diet (n = 47)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Probiotic (n = 49)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (n = 44)
Number of subjects: 93
Study: 27735851

Group type: EXPERIMENTAL
Intervention: Explaining the effectiveness of precautions
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: Amending precautionary messages for consistency
Number of subjects: 1717

Group type: EXPERIMENTAL
Intervention: Original precautionary messages
Number of subjects: 1717
Study: 24438094

Group type: EXPERIMENTAL
Intervention: Mild COPD patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 37
Study: 22722501

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (6-9 mg/d)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Oral Olanzapine (10-15 mg/d)
Number of subjects: 459
Study: 20512586

Group type: EXPERIMENTAL
Intervention: Compression Stockings (CS) during exercise and recovery
Number of subjects: 8

Group type: COMPARATOR
Intervention: No Compression Stockings (no CS) during exercise and recovery
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Compression Stockings (CS) during recovery
Number of subjects: 8

Group type: COMPARATOR
Intervention: No Compression Stockings (no CS) during recovery
Number of subjects: 8
Study: 18824933

Group type: EXPERIMENTAL
Intervention: Sit-ups (SU) test
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Push-ups (PU) test
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cross-validation of SU
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cross-validation of PU
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Paired-samples t-tests for SU
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Paired-samples t-tests for PU
Number of subjects: 100
Study: 19720897

Group type: EXPERIMENTAL
Intervention: Pemetrexed-carboplatin (pemetrexed 500 mg/m² on day 1; carboplatin AUC 5 on day 1)
Number of subjects: 908

Group type: COMPARATOR
Intervention: Etoposide-carboplatin (etoposide 100 mg/m² on days 1-3; carboplatin AUC 5 on day 1)
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Pemetrexed-carboplatin
Number of subjects: 908
Study: 15815206

Group type: EXPERIMENTAL
Intervention: Probiotic-supplemented formula containing Bifidobacterium lactis and Streptococcus thermophilus (10 viable cells each) for 15 days.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nonsupplemented formula for the entire duration (30 days).
Number of subjects: 80
Study: 11919238

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (chemotherapy, hormonal therapy, or both) for node-positive disease
Number of subjects: 8106

Group type: EXPERIMENTAL
Intervention: Combined multidrug chemotherapy plus tamoxifen for node-positive disease
Number of subjects: 8106

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy for node-negative disease
Number of subjects: 8106

Group type: EXPERIMENTAL
Intervention: Tamoxifen for node-negative tumors > or = 1 cm diagnosed in 1995
Number of subjects: 8106

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1995
Number of subjects: 8106

Group type: EXPERIMENTAL
Intervention: Both tamoxifen and combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1995
Number of subjects: 8106

Group type: EXPERIMENTAL
Intervention: Tamoxifen for node-negative tumors > or = 1 cm diagnosed in 1987
Number of subjects: 8106

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1987
Number of subjects: 8106

Group type: EXPERIMENTAL
Intervention: Both tamoxifen and combination chemotherapy for node-negative tumors > or = 1 cm diagnosed in 1987
Number of subjects: 8106
Study: 9598218

Group type: EXPERIMENTAL
Intervention: 60 mg of fenfluramine (FEN)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8185343

Group type: EXPERIMENTAL
Intervention: FUT-187 (sepimostat mesilate) 300 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FUT-187 (sepimostat mesilate) 400 mg/day
Number of subjects: 40
Study: 2820312

Group type: EXPERIMENTAL
Intervention: Vindesine (3 mg/m2 X 3) plus cisplatin (80‐120 mg/m2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Mitomycin C (8 mg/m2) plus vindesine (2 mg/m2 X 3) plus cisplatin (80‐120 mg/m2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Mitomycin C, vindesine and cisplatin
Number of subjects: 36
Study: 12947355

Group type: EXPERIMENTAL
Intervention: New therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Equivalence and noninferiority designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical differences between trial designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed guideline for reporting
Number of subjects: 0
Study: 30001547

Group type: EXPERIMENTAL
Intervention: Phonological Reading and Writing Remediation Program (24 cumulative sessions, twice a week, 30 min each)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no remediation)
Number of subjects: 20
Study: 27726426

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 24241491

Group type: EXPERIMENTAL
Intervention: sirolimus and tacrolimus
Number of subjects: 71

Group type: COMPARATOR
Intervention: methotrexate and tacrolimus
Number of subjects: 71
Study: 22495941

Group type: EXPERIMENTAL
Intervention: Escitalopram monotherapy (escitalopram and placebo)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Antidepressant combination (venlafaxine-XR and mirtazapine or escitalopram and bupropion-SR)
Number of subjects: 665

Group type: COMPARATOR
Intervention: MDD with concurrent SUD
Number of subjects: 665

Group type: COMPARATOR
Intervention: MDD without concurrent SUD
Number of subjects: 665
Study: 20403483

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 0
Study: 18763686

Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride/sodium hexametaphosphate dentifrice (SnF2/SHMP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 0.76% sodium monofluorophosphate/zinc citrate dentifrice (ZnCit/SMFP)
Number of subjects: 21
Study: 15837246

Group type: EXPERIMENTAL
Intervention: TAXUS stent
Number of subjects: 1314
Study: 12810991

Group type: EXPERIMENTAL
Intervention: Iontophoresis with alternating current (AC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iontophoresis with alternating current (AC) combined with anticholinergic drugs
Number of subjects: 0
Study: 10380089

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (3 x 500 microg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Systemic dexamethasone (0.5 mg/kg/day)
Number of subjects: 16
Study: 7483814

Group type: EXPERIMENTAL
Intervention: Recombinant staphylokinase (10 mg intravenous infusion over 30 min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Recombinant tissue-type plasminogen activator
Number of subjects: 50
Study: 1682544

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg orally per day for 10 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg orally per day for 20 or 30 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg orally per day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg orally per day for at least 20 days
Number of subjects: 24
Study: 6109991

Group type: EXPERIMENTAL
Intervention: Prosomatostatin (Pro-SS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Somatostatin (SS)
Number of subjects: 0
Study: 31997084

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus 300 mg green tea extract
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg plus 600 mg green tea extract
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg alone
Number of subjects: 12
Study: 30471953

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP-T co-administered with MenACWY-TT vaccine (Group A; n=104)
Number of subjects: 312

Group type: COMPARATOR
Intervention: DTaP-IPV-HB-PRP-T vaccine alone (Group B; n=105)
Number of subjects: 312

Group type: COMPARATOR
Intervention: MenACWY-TT vaccine alone (Group C; n=103)
Number of subjects: 312
Study: 27884241

Group type: EXPERIMENTAL
Intervention: Medical therapy alone
Number of subjects: 607
Study: 24816141

Group type: EXPERIMENTAL
Intervention: Frontal low current stimulation of gamma activity during REM sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other stimulation frequencies (not specified)
Number of subjects: 0
Study: 23050750

Group type: EXPERIMENTAL
Intervention: Propofol-ketamine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Propofol-remifentanil
Number of subjects: 37
Study: 20670451

Group type: EXPERIMENTAL
Intervention: Banha-sasim-tang
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18713194

Group type: EXPERIMENTAL
Intervention: Frailty index (FI) as a measure to describe the types of people included in the study
Number of subjects: 315
Study: 16512468

Group type: EXPERIMENTAL
Intervention: Mini laparoscopic cholecystectomy (MLC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 80
Study: 15257733

Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation + application of 8.5% w/w doxycycline gel (Atridox)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Non-surgical scaling/root planing (Control)
Number of subjects: 103
Study: 11853599

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b (IFN alpha‐2b)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Mitomycin C (MMC)
Number of subjects: 41
Study: 9193198

Group type: EXPERIMENTAL
Intervention: L-745,870 (15 mg/d)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: L-745,870
Number of subjects: 38
Study: 1539847

Group type: EXPERIMENTAL
Intervention: morphine (0.1 mg.kg‐1, iv)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: ketorolac (0.9 mg.kg‐1, iv)
Number of subjects: 95

Group type: COMPARATOR
Intervention: placebo (saline)
Number of subjects: 95
Study: 4078154

Group type: COMPARATOR
Intervention: Attention-related late positive wave (P400) in AN group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Attention-related late positive wave (P400) in PA group
Number of subjects: 37
Study: 29858913

Group type: EXPERIMENTAL
Intervention: mPNL
Number of subjects: 97

Group type: COMPARATOR
Intervention: standard PNL
Number of subjects: 97
Study: 29886062

Group type: EXPERIMENTAL
Intervention: Video feedback (VF)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control training without video feedback
Number of subjects: 38
Study: 26742474

Group type: EXPERIMENTAL
Intervention: Postdischarge mortality risk after hospitalization for heart failure
Number of subjects: 3993

Group type: EXPERIMENTAL
Intervention: Predicted mortality rate immediately after discharge
Number of subjects: 3993

Group type: EXPERIMENTAL
Intervention: Risk variation between quintiles of risk
Number of subjects: 3993

Group type: EXPERIMENTAL
Intervention: Predicted mortality risk during the 90 days preceding subsequent heart failure readmission
Number of subjects: 3993

Group type: EXPERIMENTAL
Intervention: Long-term interventions for high mortality risk patients
Number of subjects: 3993
Study: 24905206

Group type: EXPERIMENTAL
Intervention: Planning instruction based on the self‐regulated strategy development model
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard writing instruction
Number of subjects: 192
Study: 22313803

Group type: EXPERIMENTAL
Intervention: Facilitated PCI
Number of subjects: 152
Study: 19684423

Group type: EXPERIMENTAL
Intervention: Pneumatic trabeculoplasty (PNT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 32
Study: 18278698

Group type: EXPERIMENTAL
Intervention: Chemotherapy (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacogenetics and pharmacogenomics (individualisation of therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data from registries and observational trials
Number of subjects: 0
Study: 15973098

Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidopexy (SH)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Milligan-Morgan technique (MM)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 134
Study: 12618256

Group type: EXPERIMENTAL
Intervention: 400 microg sublingual misoprostol 3 h prior to vacuum aspiration (VA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No premedication for cervical ripening (Control)
Number of subjects: 100